Furthermore, Lei Z et al. found that the combination of anti-PD-L1 Atezolizumab and anti-vascular endothelial growth factor Bevacizumab prevented cisplatin-resistant ovarian cancer progression by suppressing STAT3-induced epithelial-mesenchymal transition [38]. This evidence concerns the gene STAT3 and ovarian carcinoma.